News Releases

ATLANTA , Oct. 21, 2020 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 third quarter financial results will be released on Wednesday, November 4, 2020 after the market closes.  On that day, the Company

ATLANTA , Sept. 8, 2020 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 18th Annual Morgan Stanley Global Healthcare Conference .

Conference Call and Webcast Today, September 2, 2020 at 5:00 pm ET ATLANTA , Sept. 2, 2020 /PRNewswire/ -- CryoLife, Inc. (" CryoLife "; NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has acquired Ascyrus Medical LLC (Ascyrus).

ATLANTA , Aug. 6, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in two upcoming virtual investor conferences.     CryoLife's management team will present at the upcoming Canaccord

ATLANTA , July 30, 2020 /PRNewswire/ --     Second Quarter and Recent Business Highlights: Achieved total revenues of $53.8 million in the second quarter 2020 versus $71.1 million in the second quarter of 2019 - Total revenues decreased 24% and decreased 23% on a non-GAAP constant currency basis

ATLANTA , July 21, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 second quarter financial results will be released on Thursday, July 30, 2020 after the market closes.  On that day, the Company

ATLANTA , June 19, 2020 /PRNewswire/ -- CryoLife, Inc.   (NYSE: CRY) (" CryoLife " or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced the pricing of $100 million aggregate principal amount of 4.250% convertible senior notes due 2025 (the

ATLANTA , June 18, 2020 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY) (" CryoLife " or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it intends to offer, subject to market conditions and other factors, $100,000,000 aggregate principal

Study Designed to Evaluate the Use of Apixaban in On-X Aortic Valve Patients ATLANTA , May 7, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) , a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has initiated enrollment in the PROACT Xa clinical trial,

ATLANTA , April 30, 2020 /PRNewswire/ -- First Quarter and Recent Business Highlights: Achieved total revenues of $66.4 million in the first quarter 2020 versus preliminary first quarter 2020 revenues of $65.5 million Total revenues decreased 2% and decreased 1% on a constant currency basis versus